CN115968406A - 用于治疗癌症的剪接衍生抗原的鉴定 - Google Patents

用于治疗癌症的剪接衍生抗原的鉴定 Download PDF

Info

Publication number
CN115968406A
CN115968406A CN202080092216.9A CN202080092216A CN115968406A CN 115968406 A CN115968406 A CN 115968406A CN 202080092216 A CN202080092216 A CN 202080092216A CN 115968406 A CN115968406 A CN 115968406A
Authority
CN
China
Prior art keywords
cell
tcr
peptide
seq
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080092216.9A
Other languages
English (en)
Chinese (zh)
Inventor
邢毅
罗伯特·普林斯
潘扬
亚历山大·H·李
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California San Diego UCSD
Original Assignee
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California San Diego UCSD filed Critical University of California San Diego UCSD
Publication of CN115968406A publication Critical patent/CN115968406A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/04—Libraries containing only organic compounds
    • C40B40/06—Libraries containing nucleotides or polynucleotides, or derivatives thereof
    • C40B40/08—Libraries containing RNA or DNA which encodes proteins, e.g. gene libraries
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
    • A61K35/545—Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/428—Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B30/00—ICT specially adapted for sequence analysis involving nucleotides or amino acids
    • G16B30/10—Sequence alignment; Homology search
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/47—Brain; Nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B15/00—ICT specially adapted for analysing two-dimensional [2D] or three-dimensional [3D] molecular structures, e.g. structural or functional relations or structure alignment
    • G16B15/30—Drug targeting using structural data; Docking or binding prediction
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • G16B40/10—Signal processing, e.g. from mass spectrometry [MS] or from PCR

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Developmental Biology & Embryology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Analytical Chemistry (AREA)
  • Theoretical Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Evolutionary Biology (AREA)
  • Medical Informatics (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gynecology & Obstetrics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN202080092216.9A 2019-11-08 2020-11-06 用于治疗癌症的剪接衍生抗原的鉴定 Pending CN115968406A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962932751P 2019-11-08 2019-11-08
US62/932,751 2019-11-08
US201962934914P 2019-11-13 2019-11-13
US62/934,914 2019-11-13
PCT/US2020/059476 WO2021092436A1 (en) 2019-11-08 2020-11-06 Identification of splicing-derived antigens for treating cancer

Publications (1)

Publication Number Publication Date
CN115968406A true CN115968406A (zh) 2023-04-14

Family

ID=75849568

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080092216.9A Pending CN115968406A (zh) 2019-11-08 2020-11-06 用于治疗癌症的剪接衍生抗原的鉴定

Country Status (5)

Country Link
US (1) US20220380937A1 (https=)
EP (1) EP4055182A4 (https=)
JP (1) JP2022554395A (https=)
CN (1) CN115968406A (https=)
WO (1) WO2021092436A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020144021A1 (en) * 2019-01-09 2020-07-16 British Telecommunications Public Limited Company Anomalous behaviour detection in a distributed transactional database
JP2023513605A (ja) * 2020-02-14 2023-03-31 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア がんを処置するためのスプライシング由来抗原を含む組成物および方法
EP4423116A4 (en) * 2021-10-25 2025-12-17 Univ California METHODS AND COMPOSITIONS FOR THE TREATMENT OF GLIOBLASTOM
EP4201954A1 (en) * 2021-12-22 2023-06-28 Christian-Albrechts-Universität zu Kiel Proteins and t-cells involved in chronic inflammatory diseases
US20250277013A1 (en) * 2022-05-04 2025-09-04 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts T cell receptor derived binding polypeptides
CN114891885A (zh) * 2022-05-04 2022-08-12 重庆大学附属肿瘤医院 Hdhd5-as1长链非编码rna水平检测试剂在制备卵巢癌干性诊断试剂中的应用
WO2024044786A2 (en) * 2022-08-26 2024-02-29 H. Lee Moffitt Cancer Center And Research Institute, Inc. Novel cd4+ tumor infiltrating lymphocytes for the treatment of cancer
US20260027153A1 (en) * 2023-01-17 2026-01-29 The Regents Of The University Of California Therapeutic polynucleotides encoding t cell receptor (tcr) alpha chain polypeptides and/or tcr beta chain polypeptides
WO2025050009A2 (en) * 2023-09-01 2025-03-06 Children's Hospital Medical Center Identification of targets for immunotherapy in melanoma using splicing-derived neoantigens

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105377292A (zh) * 2013-04-07 2016-03-02 博德研究所 用于个性化瘤形成疫苗的组合物和方法
US20170056486A1 (en) * 2015-08-28 2017-03-02 Immatics Biotechnologies Gmbh Novel peptides, combination of peptides and scaffolds for use in immunotherapeutic treatment of various cancers

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8021658B2 (en) * 2001-05-25 2011-09-20 Thomas Jefferson University Alternative splice forms of proteins as basis for multiple therapeutic modalities
AU2013243948A1 (en) * 2012-04-02 2014-10-30 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins associated with human disease
KR101503341B1 (ko) * 2014-03-12 2015-03-18 국립암센터 자가암항원 특이적 cd8+ t 세포의 분리 및 증식방법
KR20260039788A (ko) * 2017-10-10 2026-03-20 시애틀 프로젝트 코포레이션 핫스팟을 이용한 신생항원 동정
JP2023513605A (ja) * 2020-02-14 2023-03-31 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア がんを処置するためのスプライシング由来抗原を含む組成物および方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105377292A (zh) * 2013-04-07 2016-03-02 博德研究所 用于个性化瘤形成疫苗的组合物和方法
US20170056486A1 (en) * 2015-08-28 2017-03-02 Immatics Biotechnologies Gmbh Novel peptides, combination of peptides and scaffolds for use in immunotherapeutic treatment of various cancers

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MA ZHONGMIN 等: "Human Pancreatic Islets Express mRNA Species Encoding Two Distinct Catalytically Active Isoforms of Group VI Phospholipase A2 (iPLA2) That Arise from an Exon-skipping Mechanism of Alternative Splicing of the Transcript from the iPLA2 Gene on Chromosome 22q13.1*", 《J BIOL CHEM》, vol. 274, no. 14, 19 July 2013 (2013-07-19), pages 9607, XP002959569, DOI: 10.1074/jbc.274.14.9607 *

Also Published As

Publication number Publication date
WO2021092436A1 (en) 2021-05-14
EP4055182A4 (en) 2024-07-03
EP4055182A1 (en) 2022-09-14
JP2022554395A (ja) 2022-12-28
US20220380937A1 (en) 2022-12-01

Similar Documents

Publication Publication Date Title
CN115968406A (zh) 用于治疗癌症的剪接衍生抗原的鉴定
Trefny et al. Deletion of SNX9 alleviates CD8 T cell exhaustion for effective cellular cancer immunotherapy
CN106973568B (zh) 预测针对嵌合抗原受体疗法的治疗应答性的生物标志及其用途
US10709775B2 (en) Cells for immunotherapy engineered for targeting CD38 antigen and for CD38 gene inactivation
US20240269179A1 (en) Neoantigens as targets for immunotherapy
JP2022002525A (ja) キメラ抗原受容体発現細胞の有効性および増殖を改善するための方法
JP2021526814A5 (https=)
US12570712B2 (en) Cyclin A1 specific T cell receptors and uses thereof
JP2018533744A (ja) サイトカイン放出症候群を予測するバイオマーカー
US20190240257A1 (en) Compositions and methods for identifying functional anti-tumor t cell responses
US20250230244A1 (en) Methods and compositions comprising b7-h3 binding polypetides
JP2023513605A (ja) がんを処置するためのスプライシング由来抗原を含む組成物および方法
AU2018304173A1 (en) Antigen binding regions against fibronectin type III domains and methods of using the same
Gumpert et al. Recurrent immunogenic neoantigens and their cognate T-cell receptors in treatment-resistant metastatic prostate cancer
HK40092056A (zh) 用於治疗癌症的剪接衍生抗原的鉴定
WO2025050009A2 (en) Identification of targets for immunotherapy in melanoma using splicing-derived neoantigens
Wang et al. Peptide-Specific CARs Recognize WT1 Promiscuously Presented by Diverse HLA Class II Alleles
US20250041341A1 (en) Polypeptides targeting cd105+ cancers
US20250241953A1 (en) Tdt-specific chimeric receptors and methods of their use
WO2026059935A1 (en) Immunotherapy targeting modified kras g12v antigen
BR112020025048A2 (pt) Receptores de antígeno quimérico de bcma e usos dos mesmos
EA044007B1 (ru) Антигенсвязывающие области против доменов фибронектина типа iii и способы их применения

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40092056

Country of ref document: HK